Amha Atakilit – Insights on Inventions, Patents, and Patent Applications

Amha Atakilit is a specialist at the University of California and has 46 patents filed globally that belong to 8 patent families. Dean Sheppard, Professor, UCSF School of Medicine, is co-inventor in all of his patent applications which are assigned to the University of California, Pfizer, and Biogen.

Amha Atakilit inventions are focused on the roles of αvβ5 and αvβ8 integrin in models of common lung disease, and different methods and composition for treating and preventing disease associated with αvβ5 integrin. The table at the bottom provides further information on Amha Atakilit’s patents.

Assignees’ of Amha Atakilit Patents

All of Amha Atakilit’s patents are assigned to the University of California among which two patents are jointly owned by Pfizer, and one by Biogen.

Worldwide Coverage of Amha Atakilit Patents

Application Area of Amha Atakilit Patents

Pub NumberFiling YearAssigneeTitleApplication Area
US10597455B22018University Of CaliforniaMethods and compositions for treating and preventing disease associated with αvβ5 integrinIn the treatment of tissue fibrosis, acute lung injury and pulmonary emphysema
CA2767409C2010University of CaliforniaMethods and compositions for treating and preventing disease associated with αvβ5 integrinTreatment of Sepsis
US10005838B22016University of CaliforniaMilk fat globule epidermal growth factor 8 regulates fatty acid uptakeTreatment of Diabetes by increasing insulin sensitivity
ES2671522T32005University of CaliforniaMethods and compositions for treating and preventing a disease associated with integrin αvβ5Treatment or prevention of pulmonary edema and acute lung injury
AU2012216372B22012University of CaliforniaMethods and compositions for treating and preventing disease associated with αvβ5 integrinTreatment of acute lung injury
TW202024131A2019Pfizer, and University of CaliforniaAnti-αvβ8 antibodies and compositions and uses thereof
WO2020051333A82019Pfizer, and  University Of CaliforniaAnti-αvβ8 antibodies and compositions and uses thereof
WO2014144616A32014Biogen Inc., and University Of CaliforniaAnti-αvβ5 antibodies and uses thereofTreatment of acute lung injury, (ARDS), PE, lung fibrosis, sepsis, stroke, , cancer, and ocular neovascularization disease
Updated on September 7, 2020

Was this article helpful?

Related Articles

Leave a Comment